Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis

Annals of Internal Medicine

Volumn 120, Issue 9, 1994, Pages 771-783

  Natanson, Charles ^a   Suffredini, Anthony F ^a   Eichacker, Peter Q ^a   Danner, Robert L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTOXIN; INTERLEUKIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E5; NITRIC OXIDE; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

BACTERIAL GROWTH; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOTOXIN DETECTION; GROWTH INHIBITION; HOST RESISTANCE; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEPTIC SHOCK; TREATMENT PLANNING;

EID: 23444446083     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-120-9-199405010-00009     Document Type: Conference Paper

References (151)

1. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483-90.
2. Wiles JB, Cerra FB, Siegel JH, Border JR. The systemic septic response: does the organism matter? Crit Care Med. 1980;8:55-60.
3. Natanson C, Danner RL, Elin RJ, Hosseini JM, Peart KW, Banks SM, et al. Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest. 1989;83: 243-51.
4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest. 1992;101:1644-55.
5. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328:106-13.
6. Nathan C, Sporn M. Cytokines in context. J Cell Biol. 1991;113: 981-6.
7. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-4.
8. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982;307:1225-30.
9. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE. Endotoxemia in human septic shock. Chest. 1991;99:169-75.
10. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991:324:429-36.
11. Tenaillon A, Dhainaut JF, Letulzo Y, Schlemmer B, Solet JP, Wolff M, et al. Efficacy of P.A.F. antagonist (BN 52021) in reducing mortality of patients with severe gram-negative sepsis [Abstract]. Am Rev Respir Dis. 1993;147:A196.
12. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317:659-65.
13. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR Morb Mortal Wkly Rep. 1990;39:31-4.
14. Westphal O, Jann K, Himmelspach K. Chemistry and immunochemistry of bacterial lipopolysaccharide as cell wall antigens and endotoxins. Prog Allergy. 1983;33:9-39.
15. Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169:823-32.
16. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, et al. The cardiovascular response of normal humans to administration of endotoxin. N Engl J Med. 1989;321:280-7.
17. Greisman SE, Hornick RB, Wagner HN Jr, Woodward WE, Woodward TE. The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. J Clin Invest. 1969;48:613-29.
18. Adi S, Pollock AS, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Role of monokines in the metabolic effects of endotoxin. J Clin Invest. 1992;89:1603-9.
19. McCabe WR, Olans RN. Shock in gram-negative bacteremia: predisposing factors, pathophysiology, and treatment. In: Remington JS, Swartz MN; eds. Current Clinical Topics in Infectious Diseases. Vol. 2. New York: McGraw-Hill; 1981:121-50.
20. Cross AS, Gemski P, Sadoff JC, Orskov F, Orskov I. The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis. 1984;149:184-93.
21. Sadoff JC, Wright DC, Futrovsky S, Sidberry H, Collins H, Kaufmann B. Characterization of mouse monoclonal antibodies directed against Pseudomonas aeruginosa lipopolysaccharides. Antibiot Chemother. 1985;36:134-46.
22. Ziegler EJ, Douglas H, Sherman JE, Davis CE, Brande AI. Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant. J Immunol. 1973;111:433-8.
23. Young LS, Stevens P, Ingram J. Functional role of antibody against core glycolipid of Enterobacteriaceae. J Clin Invest. 1975;56:850-61.
24. Krieger JI, Fletcher RC, Siegel SA, Fearon DT, Neblock DS, Boutin RH, et al. Human anti-endotoxin antibody HA-1A mediates complement-dependent binding of Escherichia coli J5 lipopolysaccharide to complement receptor type 1 of human erythrocytes and neutrophils. J Infect Dis. 1993;167:865-75.
25. Heumann D, Baumgartner JD, Jacot-Guillarmod H, Glauser M. Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides. J Infect Dis. 1991;163:762-8.
26. Bruins SC, Stumacher R, Johns MA, McCabe WR. Immunization with R mutants of Salmonella minnesota. II. Comparison of the protective effect of immunization with lipid A and the Re mutant. Infect Immunol. 1977;17:16-20.
27. Miner KM, Manyak CL, Williams E, Jackson J, Jewell M, Gammon MT, et al. Characterization of murine monoclonal antibodies to Escherichia coli J5. Infect Immunol. 1986;52:56-62.
28. Warren HS, Amato SF, Pitting C, Black KM, Loiselle PM, Pasternack MS, et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med. 1993;177:89-97.
29. Baumgartner JD. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect Dis Clin North Am. 1991;5: 915-27.
30. Calandra T, Glauser MP, Schellekens J, Verhoef J. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis. 1988;158:312-19.
31. McCutchan JA, Wolf JL, Ziegler EJ, Braude AI. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infection in patients with prolonged neutropenia. Schweiz Med Wochenschr. 1983;113(Suppl 14):40-55.
32. Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, van Melle G, Klauber MR, et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 1985;2:59-63.
33. The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med. 1992; 327:234-40.
34. J5 Study Group. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis. 1992;165:695-701.
35. Young LS, Gascon R, Alam S, Bermudez LM. Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis. 1989; 11(Suppl 7):S1564-71.
36. Teng NN, Kaplan HS, Hebert JM, Moore C, Douglas H, Wunderlich A, et al. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA. 1985;82:1790-4.
37. Wheeler AP, Hardie WD, Bernard G. Studies of an anti-endotoxin antibody in preventing the physiologic changes of endotoxemia in awake sheep. Am Rev Respir Dis. 1990;142:775-81.
38. Baumgartner JD, Heumann D, Gerain J, Weinbreck P, Grau GE, Glauser MP. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med. 1990;171:889-96.
39. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991;266: 1097-1102.
40. Wenzel R, Bone RC, Fein A, Quenzer R, Shentag J, Gorelick KJ, et al. Results of a second double-blind, randomized, controlled trial of anti-endotoxin antibody E5 in gram-negative sepsis [Abstract]. Program and Abstracts of the Thirty-First Interscience Conference of Antimicrobial Agents and Chemotherapy. 1991;294.
41. Relman AS. Editorial review of protocols for clinical trials [Editor's reply]. N Engl J Med. 1990;323:1355.
42. Warren HS, Danner RL, Munford RS. Sounding board: anti-endotoxin antibodies. N Engl J Med. 1992;326:1153-7.
43. Siegel JP, Stein KE, Zoon KC. Anti-endotoxin monoclonal antibodies [the FDA reply]. N Engl J Med. 1992;327:890-1.
44. Luce JM. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med. 1993;21:1233-41
45. Hoffman WD, Pollack M, Banks SM, Koev LA, Solomon MA, Danner RL, et al. Distinct functional activities in canine septic shock of monoclonal antibodies specific for the O-polysaccharide and core regions of Escherichia coli lipopolysaccharide. J Infect Dis. 1994;169:553-61.
46. Quezado ZM, Natanson C, Alling DW, Banks SM, Koev CA, Elin RJ, et al. A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA. 1993;269:2221-7.
47. Corriveau CC, Danner RL. Endotoxin as a therapeutic target in septic shock. Infect Agents Dis. 1993;2:35-43.
48. Endres S, Cannon JG, Ghorbani R, Dempsey RA, Sisson SD, Lonnemann G, et al. In vitro production of IL-1 beta, IL-1 alpha, TNF and IL-2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol. 1989;19:2327-33.
49. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988;166:147-53.
50. Cannon GC, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990;161:79-84.
51. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81:1162-72.
52. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-4.
53. Smith JW II, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol. 1992;10:1141-52.
54. Michie HR, Spriggs DR, Manogue KR, Sherman ML, Revhaug A, O'Dwyer ST, et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 1988;104: 280-6.
55. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 1992;89:1551-7.
56. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science. 1985;229:869-71.
57. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today. 1991:12:404-10.
58. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, et al. Prognostic values of tumor necrosis factor/ cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock. J Infect Dis. 1990;161:982-7.
59. Munoz C, Carlet J, Fitting C, Misset B, Bleriot J-P, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991;88:1747-54.
60. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989;169:333-8.
61. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis. 1992;145:1016-22.
62. Boujoukos AJ, Martich GD, Supinski E, Suffredini AF. Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration. J Appl Physiol. 1993;74:3027-33.
63. Ding AH, Porteu F. Regulation of tumor necrosis factor receptors on phagocytes. Proc Soc Exp Biol Med. 1992;200:458-65.
64. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175:323-9.
65. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991;5:2567-74.
66. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor in vitro and in vivo. Proc Natl Acad Sci USA. 1992;89:4845-9.
67. Fischer E, Van Zee KJ, Marano MA, Rock CS, Kenney JS, Poutsiaka DD, et al. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood. 1992;79: 2196-2200.
68. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of septic shock syndrome. J Infect Dis. 1991;163:1177-84.
69. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immunol. 1988;56:2563-9.
70. Allendoerfer R, Magee DM, Smith JG, Bonewald L, Graybill JR. Induction of tumor necrosis factor-alpha in murine Candida albicans infection. J Infect Dis. 1993;167:1168-72.
71. Alexander HR, Sheppard BC, Jensen JC, Langstein HN, Buresh CM, Venzon D, et al. Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest. 1991; 88:34-9.
72. Van der Meer JW, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA. 1988;85: 1620-3.
73. Fisher CJ Jr, Opal SM, Dhainaut J-F, Stephens S, Zimmerman JL, Nightingale P, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med. 1993;21:318-27.
74. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock. 1990; 30:279-92.
75. Hinshaw LB, Emerson TE, Taylor FB Jr, Chang AC, Duerr M, Peer GT, et al. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J Trauma. 1992;33:568-73.
76. Ashkenazi A, Marsters SA, Capon DJ, Chama SM, Figari IS, Pennica D, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesion. Proc Natl Acad Sci USA. 1991;88:10535-9.
77. Zanetti G, Heumann D, Gérain J, Kohler J, Abbet P, Barras C, et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice: comparative efficacy of antibodies to tumor necrosis factor-α and to lipopolysaccharide. J Immunol. 1992;148:1890-7.
78. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol. 1990;145:3762-6.
79. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis. 1991;163:83-8.
80. Wherry J, Wenzel R, Wunderink R, Silverman H, Perl T, Nasraway S. et al. Monoclonal antibody to human tumor necrosis factor (TNF MAb): multicenter efficacy and safety study in patients with the sepsis syndrome. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, New Orleans, Louisiana, 17-20 October 1993, Abstract #696:246.
81. Sadoff J. Soluble TNF receptors. Presented at the Third International Congress of the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches. Munich, Germany, 5 March 1994.
82. Fisher CJ Jr, Slotner GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22:12-21.
83. Fisher CJ Jr, Dhainaut J-F, Pribble JP, Knaus WA, IL-1 Receptor Antagonist Study Group. A study evaluating the safety and efficacy of human recombinant interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: preliminary results from a phase III multicenter trial [Abstract]. Clin Intensive Care. 1993;4:8S.
84. Knaus VVA, Harrell FE, Fisher CJ Jr, Wagner DP, Opal SM, Sadoff JC, et al. The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA. 1993;270: 1233-41.
85. Zimmerman JJ, Ringer TV. Inflammatory host responses in sepsis. Crit Care Clin. 1992;8:163-89.
86. Rinaldo JE, Christman JW. Mechanisms and mediators of the adult respiratory distress syndrome. Clin Chest Med. 1990;11:621-32.
87. Bersten A, Sibbald WJ. Acute lung injury in septic shock. Crit Care Clin. 1989;5:49-77.
88. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989; 320:365-76.
89. Heflin AC Jr, Brigham KL. Prevention by granulocyte depletion of increased vascular permeability of sheep lung following endotoxemia. J Clin Invest. 1981;68:1253-60.
90. Densen P, Mandell G. Granulocytic phagocytes. In: Mandell GL, Douglas RG, Benett JE; eds. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone; 1990:81-101.
91. Repine JE, Bechler CJ. Neutrophils and adult respiratory distress syndrome: two interlocking perspectives in 1991. Am Rev Resp Dis. 1991;144:251-2.
92. Lehrer R, Ganz T, Selsted ME, Babior BM, Curnutte JT. Neutrophils and host defense. Ann Intern Med. 1988;109:127-42.
93. Young LS. Gram-negative sepsis. In: Mandell GL, Douglas RG, Benett JE; eds. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone; 1990:611-36.
94. Gabrilove JL, Jakubowski A. Biological effects and clinical applications of human colony-stimulating factors. Cancer Chemother Biol Response Modif. 1990;11:631-62.
95. Arnaout MA. Structure and function of the leukocyte adhesion molecule CD11/CD18. Blood. 1990;75:1037-50.
96. Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin-1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol. 1986;136:4548-53.
97. Doerschuk CM, Winn RK, Coxson HO, Harlan JM. CD18-dependent and independent mechanisms of neutrophil emigration in the pulmonary and systemic microcirculation of rabbits. J Immunol. 1990;144:2327-33.
98. Von Asmuth EJ, Van Der Linden CJ, Leeuwenberg JF, Buurman WA. Involvement of the CD11b/18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor alpha-induced neutrophil toxicity. J Immunol. 1991; 147:3869-75.
99. Mulligan MS, Smith CW, Anderson DC, Todd RF, Miyasaka M, Tamatani T, et al. Role of leukocyte adhesion molecules in complement-induced lung injury. J Immunol. 1993;150:2401-6.
100. Takashi K, Anderson DC. The role of the integrins in inflammation. In: Gallin JI, Goldstein IM, Snyderman R; eds. Inflammation: basic Principles and Clinical Correlates. 2nd ed. New York: Raven Press; 1992:353-406.
101. Sharrar SR, Winn RK, Nurry CE, Harlan JM, Rice CL. A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high-dose staphylococcus aureus injection in rabbits. Surgery. 1991;110:213-20.
102. Walsh CJ, Carey PD, Cook DJ, Bechard DE, Fowler AA, Sugerman HJ. Anti-CD18 antibody attenuates neutropenia and alveolar-capillary membrane injury during gram-negative sepsis. Surgery. 1991; 110:205-12.
103. Eichacker PQ, Hoffman WD, Farese A, Bank SM, Mouginis T, Richmond S, et al. Leukocyte CD11b/18 antigen-directed monoclonal antibody improves early survival and decreases hypoxemia in dogs challenged with tumor necrosis factor. Am Rev Respir Dis. 1992;145:1023-9.
104. Eichacker PQ, Hoffman WD, Farese A, Banks SM, Kuo GC, MacVittie TJ, et al. TNF but not IL-1 in dogs causes lethal lung injury and multiple organ dysfunction similar to human sepsis. J Appl Physiol. 1991;71:1979-89.
105. Eichacker PQ, Hoffman WD, Farese A, Danner RL, Suffredini AF, Waisman Y, et al. Leukocyte CD18 monoclonal antibody worsens endotoxemia and cardiovascular injury in canines with septic shock. J Appl Physiol. 1993;74:1885-92.
106. Golde DW, Baldwin GC. Myeloid growth factors. In: Gallin JI, Goldstein IM, Snyderman R; eds. Inflammation: Basic Principles and Clinical Correlates. 2nd ed. New York: Raven Press; 1992: 291-301.
107. Nelson S, Summer W, Bagby G, Nakamura C, Stewart L, Lipscomb G, et al. Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis. 1991;164:901-6.
108. Cairo MS, Plunkett JM, Mauss D, Van de ven C. Seven-day administration of recombinant human granulocyte colony stimulating factor to newborn rats: modulation of neonatal neutrophilia, myelopoieses, and group B streptococcus sepsis. Blood. 1990;76:1788-94.
109. Mooney DP, Gamelli RL, O'Reilley M, Hebert JC. Recombinant human granulocyte colony-stimulating factor and pseudomonas burn wound sepsis. Arch Surg. 1988;123:1353-7.
110. Eichacker PQ, Waisman Y, Natanson C, Farese A, Hoffman WD, Banks SM, et al. Recombinant granulocyte colony stimulating factor reduces endotoxemia and improves cardiovascular function and survival during bacterial sepsis in non-neutropenic canines [Abstract]. Clin Res. 1993;41:240.
111. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-42.
112. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature. 1988;336: 385-8.
113. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-6.
114. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA. 1990;87:5193-7.
115. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991; 88:4651-5.
116. Nathan C, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol. 1991;3:65-70.
117. Cobb JP, Cunnion RE, Danner RL. Nitric oxide as a target for therapy in septic shock. Crit Care Med. 1993;21:1261-3.
118. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-64.
119. Forsterman U, Schmidt HH, Pollock JS, Sheng H, Mitchell JA, Warner TD, et al. Isoforms of nitric oxide synthase: characterization and purification from different cell types. Biochem Pharmacol. 1991;42:1849-57.
120. Gross SS, Jaffe EA, Levi R, Kilbourn RG. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun. 1991; 178:823-9.
121. Beasley D, Schwartz JH, Brenner BM. Interleukin-1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest. 1991;87:602-8.
122. Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra FB, Simmons RL, et al. Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg. 1991;214:621-6.
123. Hibbs JB Jr, Westenfelder C, Taintor R, Vavrin Z, Kablitz C, Baranowski RL, et al. Evidence of cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest. 1992;89:867-77.
124. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA. 1990;87:3629-32.
125. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun. 1990;172:1132-8.
126. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-9.
127. Cobb JP, Natanson C, Banks SM, Koev CA, Solomon MA, Hoffman WD, et al. Nω-Amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med. 1992;176: 1175-82.
128. Estrada C, Gómez C, Martin C, Moncada S, González C. Nitric oxide mediates tumor necrosis factor-α cytotoxicity in endothelial cells. Biochem Biophys Res Commun. 1992;186:475-82.
129. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Biochemistry. 1992;89:3030-4.
130. Van Dervort AL, Yan L, Madara PJ, Cobb JP, Wesley RA, Tropea MM, et al. Nitric oxide (NO) increases endotoxin (LPS)-induced cytokine production by human neutrophils (PMNs) [Abstract]. Clin Res. 1993;41:281.
131. G-methyl-L-arginine are abolished in a canine shock model using high-dose endotoxin. Research Communications in Chemical Pathology and Pharmacology. 1992;78:57-68.
132. G-monomethyl-L-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxin shock. Biochem Biophys Res Commun. 1991;178:1135-40.
133. Parker JL, Adams HR. Selective inhibition of endothelium-dependent vasodilator capacity by Escherichia coli endotoxemia. Circ Res. 1993;72:539-51.
134. Hotchkiss RS, Karl IE, Parker JL, Adams RH. Inhibition of NO synthesis in septic shock [Letter]. Lancet. 1992;339:434-5.
135. May GR, Crook P, Moore PK, Page CP. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol. 1991;102:759-63.
136. Parker MM, Shelbamer JH, Natanson C, Alling DW, Parrillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med. 1987;15:923-9.
137. Hollenberg SM, Cunnion RE, Zimmerberg J. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol. 1993;264: (Heart Circ Physiol.): H660-3.
138. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991;338:1557-68.
139. Lorente JA, Landín L, de Pablo R, Renes E, Liste D. L-arginine pathway in the sepsis syndrome. Crit Care Med. 1993;21:1287-95.
140. Kilbourn RG, Griffith OW. Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst. 1992;84:827-31.
141. G-monomethyl-L-arginine. J Cardiovas Pharmacol. 1992;20(Suppl 12):S132-4.
142. Tolins JP, Raij L. Modulation of systemic blood pressure and renal haemodynamic responses by endothelium-derived relaxing factor (nitric oxide). In: Moncada S, Higgs EA; eds. Nitric Oxide from L-Arginine. New York: Elsevier Science; 1990:463-73.
143. Walder CE, Thiemermann C, Vane JR. The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. Br J Pharmacol. 1991;102:967-73.
144. Hutcheson IR, Whittle BR, Boughton-Smith NK. Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br J Pharmacol. 1990;101:815-20.
145. G-methylarginine. Biochem Biophys Res Commun. 1990;170:96-103.
146. G-monomethyl-L-arginine between conscious and anesthetized rats. Jpn J Pharmacol. 1991;56:245-8.
147. ω-methyl-L-arginine (NMA), a nitric oxide synthase inhibitor, in endotoxin (LPS)-challenged canines [Abstract]. Crit Care Med. 1993;21:S280.
148. Meyer J, Traber LD, Nelson S, Lentz CW, Nakazawa H, Herndon DN, et al. Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol. 1992;73:324-8.
149. Lorente JA, Landín L, Renes E, De Pablo R, Jorge P, Ródena E, et al. Role of nitric oxide in the hemodynamic changes of sepsis. Crit Care Med. 1993;21:759-67.
150. Harbrecht BG, Billiar TR, Stadler J, Demetris AJ, Ochoa JB, Curran RD, et al. Nitric oxide synthesis serves to reduce hepatic damage during acute murine endotoxemia. Crit Care Med. 1992; 20:1568-74.
151. Quezado ZM, Hoffman WD, Winkelstein JA, Yatsiv I, Koev CA, Cork LC, et al. The third component of complement protects against Escherichia coli endotoxin-induced shock and multiple organ failure. J Exp Med. 1994;179:569-78.